BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38268916)

  • 1. Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma
    Xu X; Wang MD; Xu JH; Fan ZQ; Diao YK; Chen Z; Jia HD; Liu FB; Zeng YY; Wang XM; Wu H; Qiu W; Li C; Pawlik TM; Lau WY; Shen F; Lv GY; Yang T
    Front Immunol; 2023; 14():1322233. PubMed ID: 38268916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study.
    Gou XX; Shi HY; Li C; Chen ZL; Ouyang W; Sun LY; Diao YK; Wang MD; Yao LQ; Gu LH; Pawlik TM; Lau WY; Shen F; Xue J; Yang T
    Int J Radiat Oncol Biol Phys; 2022 Oct; 114(2):238-249. PubMed ID: 35643251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.
    Li C; Wang MD; Lu L; Wu H; Yu JJ; Zhang WG; Pawlik TM; Zhang YM; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Xing H; Li ZL; Lau WY; Wu MC; Shen F; Yang T
    Hepatol Int; 2019 Nov; 13(6):736-747. PubMed ID: 31486964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis.
    Yang T; Lu JH; Lau WY; Zhang TY; Zhang H; Shen YN; Alshebeeb K; Wu MC; Schwartz M; Shen F
    J Hepatol; 2016 Mar; 64(3):583-93. PubMed ID: 26596543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors.
    Li J; Wang WQ; Zhu RH; Lv X; Wang JL; Liang BY; Zhang EL; Huang ZY
    Front Immunol; 2023; 14():1202039. PubMed ID: 37359534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data.
    Yoon JS; Song BG; Lee JH; Lee HY; Kim SW; Chang Y; Lee YB; Cho EJ; Yu SJ; Sinn DH; Kim YJ; Lee JH; Yoon JH
    BMC Cancer; 2019 May; 19(1):523. PubMed ID: 31151419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study.
    Wu H; Xing H; Liang L; Huang B; Li C; Lau WY; Zhou YH; Gu WM; Wang H; Chen TH; Zhang YM; Zeng YY; Pawlik TM; Wang MD; Wu MC; Shen F; Yang T
    Eur J Surg Oncol; 2019 Dec; 45(12):2360-2368. PubMed ID: 31543386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma.
    Tang SC; Zhang KL; Lin KY; Tang YD; Fu J; Zhou WP; Zhang JX; Kong J; He XL; Sun ZH; Luo C; Liu HZ; Lai YP; Zeng YY
    Hepatol Int; 2024 Apr; 18(2):623-635. PubMed ID: 37880566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching.
    Wu Z; Tang H; Wang L; Jin X; Lei Z; Yang P; Zhou J
    BMC Surg; 2022 Mar; 22(1):103. PubMed ID: 35313836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.
    Li L; Wu PS; Liang XM; Chen K; Zhang GL; Su QB; Huo RR; Xie RW; Huang S; Ma L; Zhong JH
    J Gastroenterol; 2023 Oct; 58(10):1043-1054. PubMed ID: 37452107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of tumor morphology with long-term prognosis after liver resection for patients with a solitary huge hepatocellular carcinoma-a multicenter propensity score matching analysis.
    Xu XF; Wu H; Li JD; Yao LQ; Huang B; Diao YK; Chen TH; Gu WM; Chen Z; Li J; Zhang YM; Wang H; Liang YJ; Zhou YH; Li C; Wang MD; Zhang CW; Pawlik TM; Lau WY; Shen F; Yang T
    Hepatobiliary Surg Nutr; 2023 Jun; 12(3):314-327. PubMed ID: 37351131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
    Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
    BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma.
    Chen GX; Qi CY; Hu WJ; Wang XH; Hua YP; Kuang M; Peng BG; Li SQ
    BMC Cancer; 2020 May; 20(1):487. PubMed ID: 32471389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy.
    Chen W; Hu S; Liu Z; Sun Y; Wu J; Shen S; Peng Z
    Hepatol Int; 2023 Apr; 17(2):406-416. PubMed ID: 36645648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of menopausal status on the survival and recurrence of sex-classified hepatocellular carcinoma after liver resection: a case-matched study with propensity score matching.
    Zhang W; Liu F; Huang J; Guo X; Dong W; Wei S; Li L; Zhu X; Zhou W; Liu H
    Aging (Albany NY); 2020 Nov; 12(24):25895-25915. PubMed ID: 33232278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis.
    Guo C; Zou X; Hong Z; Sun J; Xiao W; Sun K; Li X; Shen Y; Liang T; Bai X
    HPB (Oxford); 2021 Sep; 23(9):1427-1438. PubMed ID: 33715958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2  cm in a Propensity Score Model.
    Liu PH; Hsu CY; Hsia CY; Lee YH; Huang YH; Chiou YY; Lin HC; Huo TI
    Ann Surg; 2016 Mar; 263(3):538-45. PubMed ID: 25775062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anatomical versus non-anatomical resection for solitary hepatocellular carcinoma without macroscopic vascular invasion: A propensity score matching analysis.
    Zhao H; Chen C; Gu S; Yan X; Jia W; Mao L; Qiu Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):870-878. PubMed ID: 27671209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.
    Xia F; Zhang Q; Ndhlovu E; Zheng J; Yuan M; Gao H; Xia G
    Surg Endosc; 2024 Feb; 38(2):799-812. PubMed ID: 38062182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0-A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching analysis.
    Yang SY; Yan ML; Duan YF; Feng JK; Ye JZ; Xiang YJ; Liu ZH; Guo L; Xue J; Cheng SQ; Guo WX
    Hepatol Int; 2022 Aug; 16(4):892-905. PubMed ID: 35704267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.